Big-Name Investors Pour $100M Into DNA Therapeutics Developer Seawolf
The startup will use lipid nanoparticles to deliver DNA without viruses, aiming for re-dosable treatments for bleeding disorders and other diseases.
4 Articles
4 Articles
DNA drug developer Seawolf launches with $100 million funding, Sanofi deal - Regional Media News
Nov 16 (Reuters) - Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop DNA-based medicines. • The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics and others • San Diego-based Seawolf and Sanofi will develop treatments for bleeding diso…
DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
Nov 16 (Reuters) - Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop DNA-based medicines. • The Series A financing was backed by Vers...
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium






